Trials in relapsing multiple sclerosis have been complicated by difficulties in defining the two principal significant clinical events (relapses and disability progression) that contribute to the devastating permanent…
evaluated by age, gender, baseline Expanded Disability Status Scale score, MS duration, number of relapses in the previous year, previous treatment, previous treatment duration, and reason for switching. The primary…
Treatment-pattern data suggest that some patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) may not be receiving optimal treatment. A virtual meeting of ten expert ... discussed unmet needs in…
BIOCAD, Russia) are novel immunomodulating therapeutic options for relapsing form of multiple sclerosis (MS) treatment. The BCD-054 is a conjugate of recombinant human interferon β1a and linear polyethylene glycol…
Acrolein has been implicated as an irritating/exacerbating factor in animal models of relapsing-remitting multiple sclerosis. In animal studies, Apresoline (Hydralazine) has acted as a successful acrolein scavenging…
Background/aim: Multiple sclerosis (MS) is a chronic and debilitating inflammatory autoimmune disease of the central nervous system (CNS) that affects the myelinated axons in the CNS. Incomplete remissions occur…
Multiple sclerosis (MS) is an autoimmune disease, in which due to defective functions of CD4+ CD25+ regulatory T cells, autoreactive T lymphocytes promotes neuroaxonal degeneration in central nervous system. Tregs…
Background: Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system. Relapsing-Remitting MS (RRMS) is the most common type of MS that accounts
Havrdova E, et al. A randomized, placebo-controlled tral of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910 2. Bloomgren G, Richman S, Hotermans ... Lucas L, et al. Reducing return of…
this study was to compare the efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis patients in real-world clinical setting. Methods: We enrolled 391 patients starting either natalizumab…
Objective: To determine whether treatment efficacy on relapses do enable to predict treatment efficacy on disability worsening in multiple sclerosis patients and whether that efficacy is dependent on age. Methods…
have shown shortterm benefits of disease modifying drugs (DMDs) in reducing relapse rates in patients with multiple sclerosis (MS), the data about long-term effects is more scarce and less ... certain. The objective of…
Objective: Fingolimod, a second-line therapy for relapsing-remitting multiple sclerosis, may cause transitory effects on heart rate and atrioventricular conduction that may result in bradycardia and atrioventricular…
with unrelenting effects on memory function. Moreover, it also shows that the relapsing-remitting form of multiple sclerosis might have underlying degenerative processes that are ongoing yet undetected. It raises…
report a case of a woman with relapsing remitting multiple sclerosis presenting with tumefactive demyelination at disease onset and treated with natalizumab after failure of first-line drugs. Patient ... progressive…
Abstract Objective: To explore the abnormal intrinsic functional hubs in relapsing-remitting multiple sclerosis (RRMS) using degree centrality approach and their relationships with clinical features. Methods: Total of…
compare the cost–effectiveness of different disease-modifying therapies’ strategies for treatment of relapsing-remitting multiple sclerosis (RRMS) (Figure 1). Methods: A Markov model was developed to assess the cost
objective is to describe basal characteristics and effectiveness of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) followed for ≥12 months in routine clinical practice in Spain. Methods…
behavioral variables in the transtheoretical model of change. Methods: Patients diagnosed with relapsing-remitting multiple sclerosis and being treated with GA for the first time, whether treatment-naïve
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.